

DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

 **DCAT**
AFTER THE SHOW *A Member Company Networking Event* **BARCELONA 2016**
DON'T MISS THIS INAUGURAL EVENT...
WEDNESDAY OCTOBER 5TH • 6:00 PM – 8:30 PM • CASA LLOTJA DE MAR

1. [J&J Loses Court Ruling on Potential Biosimilar of Remicade](#)

A federal district court has issued a ruling on a summary judgment motion in favor of Celltrion and Hospira in patent-infringement lawsuits related to Johnson & Johnson's (J&J) Remicade (infliximab) that arose with respect to a potential launch of a biosimilar version of infliximab. J&J said it would appeal the decision. Remicade is J&J's top-selling drug with 2015 global sales of \$6.6 billion. [Read More](#)

2. [Novartis Expands mAb Production Capacity in France](#)

Novartis has awarded Jacobs Engineering Group a contract to expand the company's biotechnology center in Huningue, France to increase monoclonal antibody production capacity in a project worth \$100 million. The project is scheduled to be completed in four years. [Read More](#)

3. [Fresenius Kabi Plans \\$250 Million Expansion](#)

Fresenius Kabi is expanding its site in Melrose Park, Illinois to increase production capacity for injectable generic pharmaceuticals. The multi-stage \$250-million expansion is scheduled for completion in 2026. [Read More](#)

4. [Cipla Names New CEO](#)

Cipla has appointed Umang Vohra as the company's managing director and global chief executive officer, effective on September 1, 2016. Umang joined the company in October 2015 as the global chief financial and strategy officer and was elevated to global chief operating officer early this year as part of a planned progression. [Read More](#)

5. [Stada Chairman Resigns](#)

Hartmut Retzlaff has resigned as chairman of the management board of Stada AG, a Bad Vibel, Germany-based generics pharmaceutical company, due to personal circumstances. Retzlaff resigned from his office as member of the management board, which he had laid down since June 5, 2016, with effect as of August 15, 2016. [Read More](#)

6. [State of New Jersey Authorizes Tax Credits for Allergan HQ Expansion](#)

The board of the New Jersey Economic Development Authority has approved Grow New Jersey (Grow NJ) tax credits to encourage Allergan Sales, the US subsidiary of Ireland-based Allergan, to remain in New Jersey and combine four existing company locations into a 431,495-square-foot facility in Madison, New Jersey. [Read More](#)

7. [Piramal to Acquire CMO Ash Stevens](#)

Piramal Enterprises Limited has agreed to acquire Ash Stevens, a Riverview, Michigan-based CDMO for active pharmaceutical ingredients for \$42.95 million plus an earn-out consideration capped at \$10 million. With the acquisition, Piramal would gain 60,000 square feet of facilities, eight chemical drug development and production laboratories, and six full-scale production areas, including high-potency manufacturing capabilities. [Read More](#)

8. [Alcami To Expand HPAPI Capacity](#)

Alcami, a custom development and manufacturing services firm, plans to expand its manufacturing capacity for active pharmaceutical ingredients at its facility in Germantown, Wisconsin for highly potent APIs (HPAPIs). Alcami plans to invest in 2016 and 2017 toward enhancement of new and existing kilo labs to introduce the development and manufacturing of HPAPIs. [Read More](#)

9. [Samsung BioLogics Plans IPO on Korean Stock Exchange](#)

Samsung BioLogics, a contract biologics manufacturer, is planning an initial public offering (IPO) on the Korean stock exchange. The company will select lead managers for the IPO in September 2016 to decide on the timing of the listing and the volume of shares to be offered. The IPO comes as the company is investing KRW 850 billion (\$776 million) in building its third biopharmaceutical manufacturing plant in Songdo, Korea. [Read More](#)

10. [Bayers' New JV For CRISPR Technology Begins Operations](#)

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, a gene-editing company, has started its operations in Cambridge, Massachusetts. In December 2015, Bayer and CRISPR Therapeutics agreed to create a joint venture to discover, develop, and commercialize therapeutics to treat blood disorders, blindness, and congenital heart disease. The deal closed earlier this year. [Read More](#)

****Upcoming DCAT Event****

[DCAT After the Show](#)

Don't miss DCAT's inaugural networking event following CPhI Worldwide in Barcelona on Wednesday, October 5th from 6:00 PM to 8:30 PM at the beautiful Casa Llotja de Mar. Located just steps away from the Gothic Quarter and Port of Barcelona, this event offers the perfect opportunity to utilize that time between the tradeshow and your late-night dinner plans to catch up with colleagues and establish valuable industry connections.

Registration for this event is now open. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Amum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org